2 78

Cited 14 times in

Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan

Authors
 Myung-Ju AHN  ;  Chun-Ming TSAI  ;  Stefan WALZER  ;  Johanna LISTER  ;  Mijeong KANG  ;  Eun-Jin BAE  ;  Sang-We KIM  ;  Jin Hyoung KANG  ;  Joo-Hang KIM  ;  Heung Tae KIM  ;  John Wen-Cheng CHANG  ;  Elaine WRIGHT  ;  Te-Chun HSIA 
Citation
 Asia-Pacific Journal of Clinical Oncology, Vol.7(Suppl. 2) : 22-33, 2011 
Journal Title
 Asia-Pacific Journal of Clinical Oncology 
ISSN
 1743-7555 
Issue Date
2011
Abstract
AIMS: The aim of this analysis is to investigate the mean incremental costs and life expectancy associated with two first-line treatments for advanced non-squamous non-small cell lung cancer (NSCLC) in Korea and Taiwan; bevacizumab plus cisplatin and gemcitabine (BevCG) and cisplatin plus pemetrexed (CP). METHODS: A health economic (area under curve) model with three health states was developed to assess health outcomes (life-years gained [LYG]), direct costs, and incremental cost-effectiveness ratio (ICER). Progression-free survival (PFS) and overall survival (OS) were derived from randomized clinical trials and used in an indirect comparison in order to estimate their cost effectiveness. A life-time horizon was used. Costs and outcomes were discounted yearly by 5% in Korea and by 3% in Taiwan. RESULTS: The incremental LYG for the BevCG patients compared with patients treated with CP were 1.10 (13.2 months) in Korea and 1.19 (14.3 months) in Taiwan. The incremental costs were 37,439,968 ($ 33,322) in Korea and NT$ 1,910,615 ($ 64,541) in Taiwan. The incremental cost-effectiveness ratio was 34,064,835 ($ 30,318) in Korea and NT$ 1,607,960 ($ 54,317) in Taiwan. The inputs tested in one-way sensitivity analyses had very little impact on the overall cost effectiveness. CONCLUSION: This analysis shows that BevCG is more costly but is also associated with additional life-years in Korea and Taiwan. The ICER per LYG suggests that BevCG is a cost-effective therapy when compared to CP for patients with advanced NSCLC in Korea and Taiwan.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/94871
DOI
10.1111/j.1743-7563.2011.01399.x
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
Yonsei Authors
김주항(Kim, Joo Hang)
사서에게 알리기
  feedback
Full Text
http://onlinelibrary.wiley.com/doi/10.1111/j.1743-7563.2011.01399.x/abstract
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse